Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting - Its impact on clinical practice

Goel, G and Sun, W (2015) Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting - Its impact on clinical practice. Journal of Hematology and Oncology, 8 (1).

[img]
Preview
PDF
Published Version
Available under License : See the attached license file.

Download (362kB) | Preview
[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)

Abstract

© 2015 Goel and Sun. The recent FDA approval of ramucirumab (RAISE trial) has added a third agent to our existing armamentarium of angiogenesis inhibitors (bevacizumab and ziv-aflibercept) for the second-line treatment of metastatic colorectal cancer, which may have some impacts in the current clinic practice.


Share

Citation/Export:
Social Networking:
Share |

Details

Item Type: Article
Status: Published
Creators/Authors:
CreatorsEmailPitt UsernameORCID
Goel, G
Sun, Wwes45@pitt.eduWES45
Date: 28 July 2015
Date Type: Publication
Journal or Publication Title: Journal of Hematology and Oncology
Volume: 8
Number: 1
DOI or Unique Handle: 10.1186/s13045-015-0183-8
Refereed: Yes
Date Deposited: 17 Aug 2016 13:47
Last Modified: 21 Oct 2017 09:55
URI: http://d-scholarship.pitt.edu/id/eprint/29225

Metrics

Monthly Views for the past 3 years

Plum Analytics

Altmetric.com


Actions (login required)

View Item View Item